7 Pages Posted: 2 May 2013
Date Written: April 29, 2013
An important case was decided this month that may have a significant impact on access to medicines for patients in developing countries. India’s high court rejected an appeal by the pharmaceutical company Novartis to grant a patent for its anti-cancer drug Glivec. In the aftermath of this case, it is more likely other countries will follow India's lead.
Keywords: Patents, Access to Medicines, Novelty, Glivec, India
Suggested Citation: Suggested Citation
Abbott, Ryan, Of Evergreening and Efficacy: The Glivec Patent Case (April 29, 2013). GESPAM, 2011. Available at SSRN: https://ssrn.com/abstract=2258904